Skip to main content
Premium Trial:

Request an Annual Quote

SomaLogic Boosts Full-Year 2021 Revenue Guidance by 10 Percent

NEW YORK – SomaLogic on Monday said that it expects to exceed its previous full-year 2021 guidance of $66.7 million in revenues by 10 percent or more.

In a statement, SomaLogic CEO Roy Smythe said that in the first half of 2021 the company "exceeded our expectations with stronger revenue, better gross margins, faster commercial team ramp, and above-plan clinical partnerships."

SomaLogic in March entered into an agreement to merge with CM Life Sciences II, a special purpose acquisition company, or SPAC, sponsored by affiliates of Casdin Capital and Corvex Management, with the purpose of listing on the Nasdaq Global Market. The merger is expected to close in the third quarter.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.